A Phase 1 Dose Finding/Expansion Study of HLX55, A Monoclonal Antibody Targeting Tyrosine-Protein Kinase MET (C-MET) in Patients With Advanced Solide Tumors Refactory to Standard Therapy
Latest Information Update: 06 Dec 2022
At a glance
- Drugs HLX 55 (Primary)
- Indications Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Henlix Biotech
Most Recent Events
- 04 Mar 2020 According to a Henlius Biopharmaceuticals media release, the first patient was dosed in Taiwan China, in this study.
- 04 Mar 2020 Status changed from not yet recruiting to recruiting, according to a Henlius Biopharmaceuticals media release.
- 19 Jan 2020 Planned initiation date changed from 1 Nov 2019 to 1 Apr 2020.